| Regulatory Rapporteur December 2021 | MEMBERS |
| Innovation in drug-device combinations | MEMBERS |
| Practical implementation of the Union Product Database | MEMBERS |
| EU Implementation: Current State | MEMBERS |
| Regulatory progress in delivering on the promise of ATMPs | MEMBERS |
| Scenarios to consider risk | MEMBERS |
| Clinical investigations – Is coordinated CA assessment the future? | MEMBERS |
| Digitalisation: How to bring paradise into regulatory work | MEMBERS |
| Regulatory science – focus on biologicals | MEMBERS |
| Fireside chat with Emer Cooke: a review of current and future priorities | MEMBERS |
| Reliance, worksharing and recognition as 21st century regulatory tools | MEMBERS |
| Acronyms and Abbreviations | MEMBERS |
| Encouraging specific investments | MEMBERS |
| Real world evidence in regulatory decision-making | MEMBERS |
| MDR implementation – is there a future for legacy devices? | MEMBERS |
| Enhancing dialogue to foster innovation | MEMBERS |
| TOPRA Symposium 2021 Annual Lecture: Listening is only the first step | MEMBERS |
| How do I Implement IVDR? Some key practicalities | MEMBERS |
| Clinical trials of the future – patient orientated and digitally connected | MEMBERS |
| Global development strategy, which market should you go to first? | MEMBERS |